Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed that it has enclosed the Press Release on 14th May 2021 titled ‘SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension’ which is self-explanatory.
The above information is a part of company’s filings submitted to BSE.